William Matchett

William E. Matchett is an American virologist and immunologist based in Minneapolis, Minnesota. He is a visiting assistant professor of biology at St. Olaf College.

History

From August 2010-May 2013, Matchett worked as administrative assistant and then supplemental instructor at Augsburg College.^[1]

Beginning in May 2011, Matchett worked in a variety of research positions at the Mayo Clinic.^[1:1] In July 2014, he began work "creating and testing new vaccines against challenging pathogens, like Ebola, Zika, HIV, and C. difficile, in the lab of Michael Barry, PhD."^[1:2] Barry's Virology, Vector and Vaccine Engineering lab at the Mayo Clinic conducts research on gene therapy, mucosal vaccines, viral vector vaccines, oncolytic adenovirus for cancer therapy, and adenovirus vaccines.^[2]

COVID-19

Matchett was a postdoctoral associate in the Langlois Lab at the University of Minnesota from April-August 2020, publishing research on behalf of the Center for Immunology.^[3] From August 2020-August 2023, he was a postdoctoral fellow in the Lung Biology T32 Training Program at the University of Minnesota Medical School where he studied "the innate and adaptive immune responses against SARS-CoV-2 and building molecular tools for studying influenza A virus."^[4]

Matchett participated in a substudy in the National Institute of Allergy and Infectious Diseases (NIAID)-funded Adaptive COVID-19 Treatment Trial (ACTT) investigating remdesivir for the treatment of COVID-19.^[3:1]

In a June 9, 2021, article written by Beatrice Dupuy, Matchett stated that "[t]he spike protein is immunogenic, meaning it causes an immune response, but it is not a toxin," in response to Byram Bridle's warning about the safety of COVID-19 vaccines during a May 2021 interview with Alex Pierson. He accused Bridle of misrepresenting Pfizer's Japanese biodistribution study, including "leaving out key details of the study."^[5]

Since August 2023, Matchett has worked as a visiting assistant professor of biology at St. Olaf College.^[1:3]

Publications

• December 3, 2015: Antiviral Protection via RdRP-Mediated Stable Activation of Innate Immunity
  • Published in PLOS Pathogens
  • Funded by the Mayo Clinic
• December 15, 2018: A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus
  • Published in the Journal of Infectious Diseases
  • rVSV-EBOV-Luc vector provided by Heinz Feldmann
• May 1, 2019: Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques
  • Published in the Journal of Virology
• February 2, 2020: Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope
  • Published in Vaccines
• August 22, 2020: A Replicating Single-Cycle Adenovirus Vaccine Effective against Clostridium difficile
  • Published in Vaccines
  • Funded by the National Center for Advancing Translational Sciences (NCATS) and the Translational Product Development Fund (TPDF)
• September 16, 2020: SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with nonsevere disease
  • Published in Transfusion
  • Funded by the NorthShore Hospitals Foundation
• January 28, 2021: Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium
  • Published in PLOS Pathogens
  • Supported by the Minnesota Supercomputing Institute, the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) and the University of Minnesota Medical School
• April 15, 2021: Immune profiling to determine early disease trajectories associated with coronavirus disease 2019 mortality rate: a substudy from the ACTT-1 Trial
  • Published in the Journal of Infectious Diseases
  • Funded by the National Institute of Allergy and Infectious Diseases (NIAID)
• July 15, 2021: Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity
  • Published in the Journal of Immunology
  • Funded by the National Heart, Lung, and Blood Institute (NHLBI), the University of Minnesota Medical School and the Minnesota Partnership for Biotechnology and Medical Genomics
  • SARS-CoV-2 clones obtained through the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)
• October 27, 2021: Mice with diverse microbial exposure histories as a model for preclinical vaccine testing
  • Published in Cell Host Microbe
  • Funded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID) through the Centers of Excellence for Influenza Research and Surveillance (CEIRS) program
• December 16, 2021: Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography
  • Published in Nature Communications
• June 22, 2022: Boosting corrects a memory B cell defect in SARS-CoV-2 mRNA–vaccinated patients with inflammatory bowel disease
  • Published in JCI Insight
  • In collaboration with the Clinical and Translational Science Institute
  • Funded by University of Minnesota Medical School and Achieving Cures Together

External links

• LinkedIn
• ORCID
• Twitter